In this review, we present the evidence on the safety and efficacy of anticholinergic therapy for men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and emphasize the data published over the past year.
This review discusses two classes of medications whose mechanism of action attenuates the effect of acetylcholine on the LUT: anticholinergics and botulinum toxin. We review the randomized controlled trials that investigate the efficacy and side effects of anticholinergics when used in men with LUTS secondary to BPH. We emphasize new studies and developments that have been made in the past year.
Written by:
Weissbart SJ, Chughtai B, Elterman D, Lee R, Te A, Kaplan S. Are you the author?
James Buchanan Brady Department of Urology, Weill Cornell Medical College of Cornell University, 525 East 68th Street, F9West, Box 261, New York, NY, 10065, USA.
Reference: Curr Urol Rep. 2012 Dec;13(6):413-9.
doi: 10.1007/s11934-012-0276-7
PubMed Abstract
PMID: 22923069
